Natural Science > Chemistry > DG CY2020 8030

Research Title Determination of Pharmacokinetic Properties (Year 2 of 3)
Research Personnel Leader:
Staff:


Research Duration Start:
End:
1 December 2018
30 April 2022
Research Location Cavite
Research Description The program will establish the requisite in vitro and in vivo (animal) ADME-Tox assays to help identify the best iteration of the lead compounds in the drug discovery pipeline. The suite of assays can constitute the bulk of ADME-Tox package that will be required by regulatory authorities for an investigational new drug application (IND). Most of the assays to be described are in vitro, for several reasons. Firstly, they are simple, convenient, and provide a fast way of testing the drug-like properties of a lead series. Secondly, they require limited amounts of a test compound. Thirdly, SAR studies for metabolic activity are in fact more difficult to study animals because of confounding factors. Lastly, speciesrelated differences make ADME studies in animals less appealing, as they often fail to estimate human clinical outcomes.
Research Objectives 1. To determine the maximum concentration (Cmax), time to reach Cmax (Tmax), and area under the curve (AUC) after oral and intravenous administration of the lead candidates in Sprague-Dawley rats; 2. To calculate the elimination rate constant (Kel) and halflife (T1/2) of the lead candidates; 3. To calculate the absolute bioavailability (Fab) of the lead candidates.
Research Beneficiary(ies) This will benefit all parties involved in their discovery and development as joint owners of all intellectual property generated. Most importantly, patients are the ultimate beneficiaries should the drugs survive clinical trials and FDA approval.
Research Accoplishments [CY 2019] The project will provide the following pharmacokinetic parameters of the tested lead drug candidates: AUC, CMax, Tmax, Half-life and Elimination Rate Constant. Bioavailability of the candidate drugs will also be calculated. [CY 2020] The project will provide the following pharmacokinetic parameters of the tested lead drug candidates: AUC, CMax, Tmax, Half-life and Elimination Rate Constant. Bioavailability of the candidate drugs will also be calculated. [CY 2021] The project will provide the following pharmacokinetic parameters of the tested lead drug candidates: AUC, CMax, Tmax, Half-life and Elimination Rate Constant. Bioavailability of the candidate drugs will also be calculated.
Total Research Cost ₱6,841,843.85
Research Agencies Funding:
Implementing:
Cooperating:
Monitoring:

PharmalyticsCorporation


Research Budget Breakdown Year:
Year Funded:
PS:
MOOE:
EO:
Total Cost
Date Released
Amount Released








Code DG CY2020 8030
KRA Code
Priority Thrust DOST
R&D


Sector Natural Sciences
Actual Sector Chemistry
Related sectors Medical science
Entry revision: February 2021